Some Epstein-Barr virus (EBV)-directed therapies are predicted to be effective only when lytic viral replication occurs. We studied whether cyclophosphamide chemotherapy induces EBV to switch from latent to lytic phases of infection in a series of EBV-associated Burkitt lymphomas
Epstein Barr virus (EBV) and Kaposi sarcoma associated herpesvirus (KSHV) are two oncogenic human γ-...
Epstein-Barr virus (EBV) is strongly associated with a spectrum of EBV-associated lymphoproliferativ...
Most Epstein-Barr virus (EBV)-positive tumor cells contain one of the latent forms of viral infectio...
Some Epstein-Barr virus (EBV)-directed therapies are predicted to be effective only when lytic viral...
Treatment options for Epstein-Barr virus (EBV)-associated Burkitt lymphoma in Africa are limited bec...
A novel therapy for Epstein-Barr virus (EBV)-positive tumors involves the intentional induction of t...
Since the discovery in 1964 of the Epstein-Barr virus (EBV) in African Burkitt lymphoma, this virus ...
Many lymphoproliferative disorders (LPDs) are considered “EBV associated” based on detection of the ...
Epidemiological and biological studies have conclusively proved that infectious agents are among the...
Epstein-Barr virus (EBV) infects cells in latent or lytic forms, but the role of lytic infection in ...
The particular epidemiological features of Burkitt lymphoma (BL) in Tropical Africa, first described...
Epstein-Barr virus (EBV) is a ubiquitous herpesvirus, affecting up to 90% of the population. EBV was...
Epstein–Barr virus (EBV) is a ubiquitous gamma herpesvirus aetiologically linked to different lympho...
Several therapeutic strategies targeting Epstein-Barr virus (EBV)-associated tumors involve upregula...
Treatment of Epstein–Barr virus (EBV)-related lymphomas with lytic-inducing agents is an attractive ...
Epstein Barr virus (EBV) and Kaposi sarcoma associated herpesvirus (KSHV) are two oncogenic human γ-...
Epstein-Barr virus (EBV) is strongly associated with a spectrum of EBV-associated lymphoproliferativ...
Most Epstein-Barr virus (EBV)-positive tumor cells contain one of the latent forms of viral infectio...
Some Epstein-Barr virus (EBV)-directed therapies are predicted to be effective only when lytic viral...
Treatment options for Epstein-Barr virus (EBV)-associated Burkitt lymphoma in Africa are limited bec...
A novel therapy for Epstein-Barr virus (EBV)-positive tumors involves the intentional induction of t...
Since the discovery in 1964 of the Epstein-Barr virus (EBV) in African Burkitt lymphoma, this virus ...
Many lymphoproliferative disorders (LPDs) are considered “EBV associated” based on detection of the ...
Epidemiological and biological studies have conclusively proved that infectious agents are among the...
Epstein-Barr virus (EBV) infects cells in latent or lytic forms, but the role of lytic infection in ...
The particular epidemiological features of Burkitt lymphoma (BL) in Tropical Africa, first described...
Epstein-Barr virus (EBV) is a ubiquitous herpesvirus, affecting up to 90% of the population. EBV was...
Epstein–Barr virus (EBV) is a ubiquitous gamma herpesvirus aetiologically linked to different lympho...
Several therapeutic strategies targeting Epstein-Barr virus (EBV)-associated tumors involve upregula...
Treatment of Epstein–Barr virus (EBV)-related lymphomas with lytic-inducing agents is an attractive ...
Epstein Barr virus (EBV) and Kaposi sarcoma associated herpesvirus (KSHV) are two oncogenic human γ-...
Epstein-Barr virus (EBV) is strongly associated with a spectrum of EBV-associated lymphoproliferativ...
Most Epstein-Barr virus (EBV)-positive tumor cells contain one of the latent forms of viral infectio...